Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours
- PMID: 23322194
- PMCID: PMC3566824
- DOI: 10.1038/bjc.2012.560
Validation of the EORTC QLQ-GINET21 questionnaire for assessing quality of life of patients with gastrointestinal neuroendocrine tumours
Abstract
Background: Quality of life is an important end point in clinical trials, yet there are few quality of life questionnaires for neuroendocrine tumours.
Methods: This international multicentre validation study assesses the QLQ-GINET21 Quality of Life Questionnaire in 253 patients with gastrointestinal neuroendocrine tumours. All patients were requested to complete two quality of life questionnaires - the EORTC Core Quality of Life questionnaire (QLQ-C30) and the QLQ-GINET21 - at baseline, and at 3 and 6 months post-baseline; the psychometric properties of the questionnaire were then analysed.
Results: Analysis of QLQ-GINET21 scales confirmed appropriate aggregation of the items, except for treatment-related symptoms, where weight gain showed low correlation with other questions in the scale; weight gain was therefore analysed as a single item. Internal consistency of scales using Cronbach's α coefficient was >0.7 for all parts of the QLQ-GINET21 at 6 months. Intraclass correlation was >0.85 for all scales. Discriminant validity was confirmed, with values <0.70 for all scales compared with each other.Scores changed in accordance with alterations in performance status and in response to expected clinical changes after therapies. Mean scores were similar for pancreatic and other tumours.
Conclusion: The QLQ-GINET21 is a valid and responsive tool for assessing quality of life in the gut, pancreas and liver neuroendocrine tumours.
Figures
Similar articles
-
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).Health Qual Life Outcomes. 2021 Jan 30;19(1):38. doi: 10.1186/s12955-021-01688-x. Health Qual Life Outcomes. 2021. PMID: 33516211 Free PMC article.
-
Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours.Eur J Cancer. 2006 Mar;42(4):477-84. doi: 10.1016/j.ejca.2005.10.025. Epub 2006 Jan 18. Eur J Cancer. 2006. PMID: 16412628
-
International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26.BMC Cancer. 2018 Nov 12;18(1):1104. doi: 10.1186/s12885-018-5036-8. BMC Cancer. 2018. PMID: 30419889 Free PMC article.
-
Psychometric validation of the Moroccan version of the EORTC QLQ-C30 in colorectal Cancer patients: cross-sectional study and systematic literature review.BMC Cancer. 2021 Jan 27;21(1):99. doi: 10.1186/s12885-021-07793-w. BMC Cancer. 2021. PMID: 33499819 Free PMC article.
-
Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review.Support Care Cancer. 2016 Aug;24(8):3661-8. doi: 10.1007/s00520-016-3270-7. Epub 2016 May 18. Support Care Cancer. 2016. PMID: 27193118 Review.
Cited by
-
Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms.J Gastrointest Surg. 2019 Jan;23(1):122-134. doi: 10.1007/s11605-018-3986-4. Epub 2018 Oct 17. J Gastrointest Surg. 2019. PMID: 30334178 Free PMC article.
-
Younger Age and Parenchyma-Sparing Surgery Positively Affected Long-Term Health-Related Quality of Life after Surgery for Pancreatic Neuroendocrine Neoplasms.J Clin Med. 2023 Oct 14;12(20):6529. doi: 10.3390/jcm12206529. J Clin Med. 2023. PMID: 37892667 Free PMC article.
-
Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities.Pharmacoecon Open. 2021 Dec;5(4):715-725. doi: 10.1007/s41669-021-00280-9. Epub 2021 Jul 14. Pharmacoecon Open. 2021. PMID: 34260017 Free PMC article.
-
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).Health Qual Life Outcomes. 2021 Jan 30;19(1):38. doi: 10.1186/s12955-021-01688-x. Health Qual Life Outcomes. 2021. PMID: 33516211 Free PMC article.
-
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study.Front Med (Lausanne). 2020 Dec 23;7:598438. doi: 10.3389/fmed.2020.598438. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33425946 Free PMC article.
References
-
- Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009;16 (3:885–894. - PubMed
-
- Bonett DG. Sample size requirements for testing and estimating coefficient alpha. J Educ Behav Stat. 2002;27:335–340.
-
- Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11 (3:570–579. - PubMed
-
- Cronbach LJ, Warrington WG. Time-limit tests: estimating their reliability and degree of speeding. Psychometrika. 1951;16 (2:167–188. - PubMed
-
- Cull A, Sprangers M, Bjordal K, Aaronson N, West K, Bottomley A.2002. EORTC Quality of Life Group translation procedure Available at: http://groupseortcbe/qol/downloads/200202translation_manualpdf
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical